Stock Traders Purchase Large Volume of Veru Call Options (NASDAQ:VERU)

Veru Inc. (NASDAQ:VERU) saw unusually large options trading activity on Tuesday. Stock traders purchased 8,511 call options on the company. This is an increase of 500% compared to the average daily volume of 1,418 call options.

Institutional Investors Weigh In On Veru

Several institutional investors have recently modified their holdings of the business. Zacks Investment Management bought a new position in Veru during the 3rd quarter valued at about $25,000. Gladstone Institutional Advisory LLC lifted its position in Veru by 34.2% during the third quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company’s stock valued at $44,000 after purchasing an additional 14,500 shares during the period. SG Americas Securities LLC boosted its holdings in Veru by 185.9% in the third quarter. SG Americas Securities LLC now owns 66,128 shares of the company’s stock worth $51,000 after purchasing an additional 42,997 shares during the last quarter. Weaver Consulting Group raised its stake in Veru by 41.0% during the 4th quarter. Weaver Consulting Group now owns 69,705 shares of the company’s stock valued at $45,000 after buying an additional 20,280 shares during the last quarter. Finally, Jane Street Group LLC lifted its holdings in shares of Veru by 142.8% during the 3rd quarter. Jane Street Group LLC now owns 96,454 shares of the company’s stock valued at $74,000 after buying an additional 56,736 shares during the period. 47.16% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

VERU has been the topic of several research reports. Oppenheimer restated an “outperform” rating and set a $5.00 price target on shares of Veru in a research report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Veru in a research report on Thursday, January 2nd.

Veru Stock Performance

Shares of VERU traded up $0.15 during trading hours on Tuesday, hitting $1.13. The company had a trading volume of 3,977,838 shares, compared to its average volume of 2,487,812. The stock has a market capitalization of $165.41 million, a price-to-earnings ratio of -4.09 and a beta of -0.53. The firm has a fifty day moving average price of $0.70 and a 200-day moving average price of $0.80. Veru has a 52-week low of $0.36 and a 52-week high of $1.92.

Veru (NASDAQ:VERU) last announced its quarterly earnings results on Monday, December 16th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. Veru had a negative net margin of 223.85% and a negative return on equity of 92.88%. Research analysts anticipate that Veru will post -0.26 earnings per share for the current fiscal year.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.